Article citationsMore>>

See, W.A., Wirth, M.P., McLeod, D.G., Iversen, P., Klimberg, I., Gleason, D., Chodak, G., Montie, J., Tyrrell, C., Wallace, D.M.A., Delaere, K.P.J., Vaage, S., Tammela, T.L.J., Lukkarinen, O., Persson, B.-E., Carrol, K. and Kolvenbag, G.J.C.M. (2002) Bicalutamide as Immediate Therapy Either Alone or as Adjuvant to Standard Care of Patients with Localized or Locally Advanced Prostate Cancer: First Analysis of the Early Prostate Cancer Program. The Journal of Urology, 168, 429-435.
http://dx.doi.org/10.1016/S0022-5347(05)64652-6

has been cited by the following article:

• TITLE: Molecular Modeling, Docking and ADMET of Dimethylthiohydantoin Derivatives for Prostate Cancer Treatment

  AUTHORS: Khaled Lotfy

  KEYWORDS: Androgen Receptor, Prostate Cancer, Molecular Modeling, Molecular Docking, ADMET

  JOURNAL NAME: Journal of Biophysical Chemistry, Vol.6 No.4, November 4, 2015

  ABSTRACT: In silico technique was applied to screen potential of 16 compounds of 5,5-dimethylthiohydantoin derivatives as androgen antagonist. The 3D structure of the protein was obtained from PDB database. Docking analysis of the compounds was performed using hex docking. Molecular modeling analysis exhibits relatively low LUMO-HOMO energy gap of the studied molecules, indicating that it would be kinetically stable. None of the compounds violated Lipinski’s parameters, making them potentially promising agents for biological activities. The title compounds exhibited the lowest docking energy of protein-ligand complex. Finally, the results indicate that these compounds are potentially as an androgen antagonist, and expected to be effective in prostate cancer treatment.